# An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

Study · id `cardio:ct-nct03775421` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03775421](<https://clinicaltrials.gov/study/NCT03775421>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03775421

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 112 participants.

## Technical summary

Registry record NCT03775421. Allocation not applicable; no masking; primary purpose treatment. Start 2019-04-11 (actual); primary completion 2022-01-18 (actual). Results posted on 2023-03-07.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT03775421, source copy `cardio:ctgov-nct03775421-2023-03-07`, retrieved 2026-10-26)
- Started: 2019-04-11 (actual) (ClinicalTrials.gov record NCT03775421, source copy `cardio:ctgov-nct03775421-2023-03-07`, retrieved 2026-10-26)
- Primary completion: 2022-01-18 (actual) (ClinicalTrials.gov record NCT03775421, source copy `cardio:ctgov-nct03775421-2023-03-07`, retrieved 2026-10-26)
- Completion: 2022-01-18 (actual) (ClinicalTrials.gov record NCT03775421, source copy `cardio:ctgov-nct03775421-2023-03-07`, retrieved 2026-10-26)
- Results first posted: 2023-03-07 (ClinicalTrials.gov record NCT03775421, source copy `cardio:ctgov-nct03775421-2023-03-07`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; China; Czechia; Denmark; France; New Zealand; Poland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT03775421, source copy `cardio:ctgov-nct03775421-2023-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03775421-2023-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
- Acronym: RUBATO OL
- Condition: Congenital Heart Disease With Fontan Circulation
- Intervention (Drug): macitentan 10 mg
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY
- Collaborator: Covance
- Collaborator class: INDUSTRY
- Collaborator: Henry Ford Health System
- Collaborator class: OTHER
- Collaborator: Almac Clinical Technologies
- Collaborator class: INDUSTRY
- Collaborator: ActiGraph LLC
- Collaborator class: OTHER
- Collaborator: Medidata Solutions
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)
- Registry lists this organization as a collaborator: Covance (`cardio:org-covance`)
- Registry lists this organization as a collaborator: Medidata Solutions (`cardio:org-medidata-solutions`)

## Provenance

Content hash: 60dfe5d75f35d2b00291df015a73df34d3180875193301e336f01ef927fc3999
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
